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Abstract In this study we demonstrate that exposure of
cultured endothelial cells to homocysteine significantly accel-
erates the rate of endothelial senescence. Examination of
telomere length demonstrates that homocysteine increases the
amount of telomere length lost per population doubling. The
effects of homocysteine on both senescence and telomere length
are inhibited by treatment with the peroxide scavenger catalase.
Chronic exposure of endothelial cells to homocysteine also
increases the expression of two surface molecules linked to
vascular disease, intracellular adhesion molecule-1 (ICAM-1)
and plasminogen activator inhibitor-1 (PAI-1). Interestingly, the
level of expression of both ICAM-1 and PAI-1 correlates with
the degree of endothelial senescence. Taken together, these
results suggest that homocysteine accelerates the rate of cellular
senescence through a redox-dependent pathway. In addition, it
suggests that chronic oxidative stress in the vessel wall may
hasten the rate of senescence and that the senescent endothelial
cell may in turn be pro-atherogenic.
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1. Introduction
The incidence of atherosclerotic disease dramatically in-
creases as a function of age, however there is presently no
de¢ned mechanistic link between aging and vascular disease.
On a cellular level, aging is often de¢ned as replicative sen-
escence. This is a process that occurs in primary cells in cul-
ture wherein after a certain number of population doublings,
cells enter a viable but growth-arrested state. Phenotypically,
the senescent state is characterized by an unresponsiveness to
serum stimulation, the development of an enlarged and £at-
tened morphology and the emergence of an endogenous sen-
escence associated L-galactosidase activity [1].
The entry of cells into the senescent state is poorly under-
stood. Of potential relevance is the observation that expres-
sion of either oncogenic forms of the small GTPase ras or
over expression of the tumor suppressor gene products p53
or Rb appear capable of triggering the senescent phenotype in
certain cells [2^4]. Interestingly, both ras and p53 can regulate
the intracellular redox state [5^7]. As such, these studies are
consistent with a 40 year old hypothesis linking the level of
intracellular ROS to aging [8,9].
Another factor that appears to limit the life span of human
cells in culture is telomere length. Telomeres are composed of
a repeated nucleotide sequence on the ends of chromosomes.
Each cell division results in the shortening of telomere length.
It is generally believed that when telomeres reach a critical
length, a signal is activated that initiates the senescent pro-
gram. This has given rise to the hypothesis that telomeres act
as mitotic clocks to regulate lifespan [10]. It is presently un-
clear how, if at all, ROS interact with telomere length to
regulate lifespan.
In this report, we have attempted to begin to understand
the connection between atherosclerosis and aging. In particu-
lar, we have sought to understand whether agents such as
homocysteine that accelerate atherosclerosis also accelerate
senescence and whether, in turn, the phenotype of the senes-
cent cell may be pro-atherogenic.
2. Materials and methods
2.1. Cell culture and senescence associated L-galactosidase (SA-L-gal)
activity
Human umbilical venous endothelial cells (HUVECS) were ob-
tained from Clonetics and used beginning at passage 3. Cells were
maintained in endothelial growth media (EGM, Clonetics) supple-
mented with 20% fetal calf serum. Cells were plated at a density of
2U105 and fresh media provided every 48 h. DL-Homocysteine was
obtained from Sigma and puri¢ed catalase from Calbiochem. Since
previous studies have indicated that many of the biological e¡ects of
homocysteine require the addition of copper [11], 4 WM CuSO4 was
added to all homocysteine treated dishes. The addition of copper
alone had no e¡ect on the rate of endothelial senescence (data not
shown). SA-L-gal activity was detected according to the procedure of
Dimri et al. [1]. Quanti¢cation of SA-L-gal cells was obtained by
counting four random ¢elds per dish and assessing the percentage
of SA-L-gal positive cells from at least 150 cells per ¢eld.
2.2. Measurement of telomere terminal restriction fragment (TRF)
length
Genomic DNA was isolated by standard means (Genomic DNA
Puri¢cation Kit, Promega) and 3^5 Wg digested overnight at 37‡C
with 30 U of Rsa1 and Hinf1 (Gibco/BRL). Telomere repeat oligo-
nucleotides were labeled with [Q-P-32]ATP and hybridization was car-
ried out at 60‡C for 2 h in QuikHyb (Stratagene) followed by two
washes with 5USSPE for 30 min at 60‡C and then with 0.1USSPE
for three 10 min washes at room temperature. Mean TRF length was
determined by 1D Image Analysis Software from Kodak. This soft-
ware allows quanti¢cation of the hybridization signal and subsequent
determination of the mean signal intensity.
2.3. FACS analysis and Western blot analysis
Endothelial cells were detached by 5 mM EDTA in PBS and
washed once with PBS containing 1% BSA. To detect intracellular
adhesion molecule-1 (ICAM-1) expression, the suspended cells were
incubated with £uorescently-labeled human ICAM-1 antibody (Beck-
man-Coulter) on ice for 30 min and washed twice with PBS contain-
ing 1% BSA. After washing, the cells were resuspended in PBS^BSA
and analyzed by FACS. To assess levels of plasminogen activator
inhibitor-1 (PAI-1), the suspended cells were analyzed by indirect
immuno£uorescence by ¢rst incubating with mouse monoclonal anti-
body to human PAI-1 (America Diagnostica) and then with an anti-
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 2 7 8 - 3
*Corresponding author. Fax: (1)-301-402 0888.
E-mail: ¢nkelt@gwgate.nhlbi.nih.gov
FEBS 23419 9-3-00
FEBS 23419FEBS Letters 470 (2000) 20^24
mouse £uorescein conjugated second antibody (Boehringer Mann-
heim). For detection of PAI-1 levels, 20 Wg protein cell lysate per
lane were analyzed by 12% SDS^PAGE gel and transferred to Protran
membrane (Schleicher and Schuell). The membrane was incubated
with 5 Wg/ml mouse antibody to human PAI-1 at room temperature
for 1 h. The signal was detected by enhanced chemiluminescence
(Amersham) as previously described [12].
3. Results
To identify whether homocysteine treatment altered the rate
of senescence, primary cultures of endothelial cells were grown
in the presence or absence of homocysteine and subsequently
evaluated for evidence of senescence using neutral pH endog-
enous senescence associated L-galactosidase activity (SA-L-
gal). As demonstrated in Fig. 1, the e¡ects of homocysteine
on SA-L-gal activity were seen with doses as low as 50 WM,
although the results were more pronounced at higher concen-
trations. No e¡ects on endothelial senescence were observed
when equal concentrations of cysteine were used as a control
(data not shown). Over the 25 day period in culture, homo-
cysteine produced as much as a 4^5-fold increase in the per-
centage of senescent endothelial cells.
We next examined whether homocysteine altered the rate at
which endothelial cells shorten their telomeres. Genomic
DNA was harvested from endothelial cells grown in the pres-
ence or absence of homocysteine and telomere length meas-
ured by Southern blotting. As demonstrated in Fig. 2A, in
control cells, as expected, the mean telomere length decreased
as a function of days in culture. The apparent rate of telomere
shortening was increased in the homocysteine treated cells.
Since homocysteine treated cells grew at a slower rate then
untreated cells, the di¡erence in telomere shortening was even
more apparent when telomere length was plotted as a function
of population doublings (Fig. 2B).
Many of the atherogenic e¡ects of homocysteine have been
ascribed to its ability to increase hydrogen peroxide genera-
tion [11]. To understand whether the e¡ects of homocysteine
on endothelial senescence were mediated by increasing hydro-
gen peroxide levels we analyzed the ability of the peroxide-
scavenging protein catalase to rescue cells. As demonstrated in
Fig. 3, the increase in SA-L-gal positive cells induced by ho-
mocysteine could be attenuated in a dose-dependent manner
by catalase treatment. Similarly, as seen in Fig. 4A, the telo-
mere length of endothelial cells grown for 15 days in the
presence of both catalase and homocysteine appeared inter-
mediate in length between untreated cells and those treated
with homocysteine treatment alone. A mean rate of telomere
loss per population doubling was obtained by dividing the
calculated loss in telomere length over a 15 day period by
the number of population doublings over that same period.
As demonstrated in Fig. 4B, it was observed that homocys-
teine treatment resulted in a nearly three-fold increase in the
rate of telomere shortening and that this e¡ect was attenuated
by catalase addition.
We next attempted to more fully characterize the senescent
state of homocysteine-treated endothelial cells. In particular
we attempted to analyze the expression of surface molecules
Fig. 1. Homocysteine accelerates endothelial senescence. Levels of
SA-L-gal positive cells as a function of homocysteine concentration.
Closed square, no treatment; open square, 50 WM homocysteine;
closed circle, 500 WM homocysteine; open circle, 750 WM homocys-
teine. All results are the mean þ S.D. of triplicate cultures.
Fig. 2. Homocysteine accelerates the rate of telomere shortening. A: Southern blot analysis for telomeric length. The calculated mean telomere
length, computed by densometric scanning as described in Section 2, is denoted by a white line. B: Mean telomere length from duplicate sam-
ples are plotted as a function of population doublings in untreated (square) and homocysteine-treated cells (triangle).
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which appear to be over expressed on senescent cells and that
may contribute to atherosclerosis. As shown in Fig. 5A,
FACS analysis of control and homocysteine treated cells dem-
onstrated that surface expression of ICAM-1 was increased
following chronic homocysteine treatment. To further extend
the relationship between homocysteine treatment, senescence
and ICAM-1 expression, we sorted homocysteine-treated cells
based solely on their level of ICAM-1 expression. As demon-
strated in Fig. 5B, the level of surface ICAM-1 expression was
a good predictor of the degree of senescence. In particular,
homocysteine-treated cells with the highest ICAM-1 (top 10%
level of expression) expression had approximately 5-fold high-
er rates of senescence then homocysteine treated cells with the
lowest (bottom 10%) ICAM-1 expression.
We performed a similar analysis with another surface mol-
ecule PAI-1, whose expression is increased in certain senescent
cells and whose expression might be viewed as pro-atherogen-
ic [13,14]. As demonstrated in Fig. 6A, by FACS analysis
homocysteine treatment resulted in a signi¢cant increase in
PAI-1 surface expression. Similarly, by Western blot analysis,
homocysteine resulted in an increase in total PAI-1 protein
levels (Fig. 6B). When homocysteine-treated cells were sorted
based on PAI-1 expression and subsequently assayed for the
degree of senescence, we again observed a signi¢cant correla-
tion between the degree of PAI-1 expression and the percent-
age of SA-L-gal positive cells (Fig. 6C).
4. Discussion
In this report we demonstrate that homocysteine treatment
results in an increase in the rate of endothelial senescence.
Interestingly, the rate of telomere shortening in homocys-
teine-treated cells is signi¢cantly increased when compared
to control endothelial cells. These results argue that the
amount of telomere loss is not strictly a function of the num-
ber of cellular divisions, but can also be modulated by various
intracellular processes. The observation that catalase reverses,
in part, the e¡ects of homocysteine on the rate of telomere
loss/population doubling suggests that the intracellular redox
state is one such intracellular variable. As such, these results
provide one potential mechanism linking increased ROS levels
and telomere length to the development of senescence. It
should be noted that we saw no e¡ects on endothelial senes-
cence when homocysteine was used in the absence of copper
(unpublished observations). Although serum levels of free
copper are low, a variety of evidence suggests that in the
vessel wall, copper bound primarily to ceruloplasmin can con-
tribute to local redox-dependent reactions [15^17].
It is presently unclear what role cellular aging has in the
atherosclerotic processes. Previous studies have examined te-
lomere length from human blood vessels obtained at autopsy
[18]. Interestingly, genomic DNA isolated from areas prone to
atherosclerosis had shorter telomere length when compared to
adjacent non-diseased areas. Another potential link between
aging and atherosclerosis comes from patients with Werner’s
Fig. 3. Catalase inhibits homocysteine-induced senescence. Levels of
SA-L-gal positive cells after 5 days in the presence of homocysteine
(750 WM) and indicated amounts of catalase (U/ml). Results are
mean þ S.D. of triplicate cultures. * indicates P6 0.05 compared to
cells not treated with catalase.
Fig. 4. Catalase inhibits homocysteine-induced changes in telomere length. A: Southern blot analysis for telomere length in endothelial cells
maintained in culture for 15 days with either no treatment (lane 1), homocysteine treatment only (lane 3)or homocysteine plus catalase (lane 2).
B: Averaged calculated telomere shortening per population doubling in untreated, homocysteine-treated (750 WM), or cells treated with homo-
cysteine (750 WM) and catalase (7500 U/ml). Results are the mean quotient of three separate determinations for telomere length and population
doublings.
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syndrome, a disease of accelerated aging. The disease is in-
herited in an autosomal recessive fashion and the disease gene
has recently been identi¢ed as a DNA helicase [19]. On a
clinical basis, although patients have a number of aging re-
lated disorders, the leading cause of death in a¡ected individ-
uals is atherosclerotic disease. Consistent with what we have
observed in our in vitro studies, at least some individuals with
Werner’s contain high serum levels of ICAM-1 and PAI-1
[20]. It is tempting to speculate that accelerated aging of the
vessel wall may play a primary role in the vascular disease
observed.
In summary, our results demonstrate that a link exists be-
tween chronic exposure to homocysteine and the rate of sen-
escence. In addition, the senescent endothelial cell exhibits a
pro-atherogenic phenotype as exhibited by high ICAM-1 and
PAI-1 expression. The ability of homocysteine to increase
telomere shortening and senescence is signi¢cantly attenuated
by the peroxide scavenger catalase. These results raise the
possibility that one e¡ect of chronic oxidative stress may be
to accelerate the rate of vessel wall aging. The notion that a
localized accumulation of senescent cells within the vessel wall
may in turn be pro-atherogenic provides one potential expla-
nation for the steep rise in atherosclerotic disease with ad-
vancing age.
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